LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter and full year ended December 31, 2022 and issued guidance for 2023.
They include new generalist-friendly labels for the traditional but obscurely named four stages of HF that, it is hoped, will have wider reach and expand the use of effective therapies.